First Trust Cloud Computing ETF vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? First Trust Cloud Computing ETF trades at $169.97 (market cap $3.46B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.34 (market cap $2.28B). The key difference: First Trust Cloud Computing ETF is the larger of the two by market cap, and First Trust Cloud Computing ETF is trading nearer its 52-week high, SELLAS Life Sciences Group Inc. Common Stock nearer its low. Which is the better fit depends on your goals.
| SKYY | SLS | |
|---|---|---|
Market Cap | $3.46B | $2.28B |
Volume | 180,124 | 3,128,960 |
52-Week High | $171.01 | $15.46 |
52-Week Low | $104.16 | $1.39 |
Typical Hold Time | 84 Days | — |
Sector | — | Health |
Enterprise Value | — | $2.15B |
Signals from Pluang's Aura AI — not financial advice
SKYY, the First Trust Cloud Computing ETF, trades at $170.78, near its 52-week high, with a slight daily decline of 0.13%. Technical indicators show a bullish trend from moving averages, while oscillators are neutral. Recent news highlights the ETF reaching new highs, driven by AI and cloud computing demand, with institutional adjustments in holdings. Financial ratios are not applicable as this is an ETF tracking a basket of cloud computing stocks.
The outlook for SKYY is positive, supported by secular trends in AI adoption and cloud infrastructure spending. Risks include market volatility and sector concentration, but the ETF offers diversified exposure without heavy reliance on mega-cap tech. Analyst sentiment is generally favorable, focusing on long-term growth opportunities in the cloud computing sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →